Growth Metrics

Gilead Sciences (GILD) Short term Debt (2016 - 2026)

Gilead Sciences filings provide 17 years of Short term Debt readings, the most recent being $2.8 billion for Q4 2025.

  • On a quarterly basis, Short term Debt rose 54.66% to $2.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 billion, a 54.66% increase, with the full-year FY2025 number at $2.8 billion, up 54.66% from a year prior.
  • Short term Debt hit $2.8 billion in Q4 2025 for Gilead Sciences, roughly flat from $2.8 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.0 billion in Q2 2023 to a low of $1.0 billion in Q2 2022.
  • Median Short term Debt over the past 5 years was $2.3 billion (2021), compared with a mean of $2.3 billion.
  • Biggest five-year swings in Short term Debt: skyrocketed 295.4% in 2023 and later tumbled 55.16% in 2024.
  • Gilead Sciences' Short term Debt stood at $1.5 billion in 2021, then skyrocketed by 49.93% to $2.3 billion in 2022, then fell by 20.9% to $1.8 billion in 2023, then rose by 0.95% to $1.8 billion in 2024, then soared by 54.66% to $2.8 billion in 2025.
  • The last three reported values for Short term Debt were $2.8 billion (Q4 2025), $2.8 billion (Q3 2025), and $2.8 billion (Q2 2025) per Business Quant data.